SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Acquired by Jacobi Capital Management LLC

Jacobi Capital Management LLC increased its stake in SPDR S&P Biotech ETF (NYSEARCA:XBIGet Rating) by 14.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,615 shares of the exchange traded fund’s stock after acquiring an additional 595 shares during the period. Jacobi Capital Management LLC’s holdings in SPDR S&P Biotech ETF were worth $415,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of XBI. D.A. Davidson & CO. raised its stake in SPDR S&P Biotech ETF by 9.3% in the fourth quarter. D.A. Davidson & CO. now owns 10,412 shares of the exchange traded fund’s stock valued at $1,166,000 after buying an additional 886 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in SPDR S&P Biotech ETF by 3.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,049 shares of the exchange traded fund’s stock valued at $2,725,000 after buying an additional 764 shares in the last quarter. Pinnacle Associates Ltd. raised its stake in SPDR S&P Biotech ETF by 33.8% in the fourth quarter. Pinnacle Associates Ltd. now owns 17,434 shares of the exchange traded fund’s stock valued at $1,952,000 after buying an additional 4,408 shares in the last quarter. Sigma Planning Corp raised its stake in SPDR S&P Biotech ETF by 9.4% in the fourth quarter. Sigma Planning Corp now owns 9,949 shares of the exchange traded fund’s stock valued at $1,114,000 after buying an additional 858 shares in the last quarter. Finally, Princeton Global Asset Management LLC acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at $129,000.

SPDR S&P Biotech ETF Stock Performance

SPDR S&P Biotech ETF stock opened at $92.30 on Friday. The stock’s fifty day moving average is $76.52 and its two-hundred day moving average is $81.85. SPDR S&P Biotech ETF has a 1-year low of $61.78 and a 1-year high of $136.61.

SPDR S&P Biotech ETF Profile

(Get Rating)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Stories

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIGet Rating).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.